Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 46.64%
March 31, 2026 46.28%
December 31, 2025 45.47%
September 30, 2025 45.62%
June 30, 2025 43.84%
March 31, 2025 45.82%
December 31, 2024 45.92%
September 30, 2024 43.50%
June 30, 2024 44.34%
March 31, 2024 45.34%
December 31, 2023 41.61%
September 30, 2023 43.99%
June 30, 2023 43.06%
March 31, 2023 45.03%
December 31, 2022 41.02%
September 30, 2022 40.64%
June 30, 2022 38.58%
March 31, 2022 42.24%
December 31, 2021 40.84%
September 30, 2021 46.89%
June 30, 2021 46.26%
March 31, 2021 52.13%
December 31, 2020 46.77%
September 30, 2020 48.24%
June 30, 2020 49.21%
Date Value
March 31, 2020 44.25%
December 31, 2019 43.04%
September 30, 2019 42.92%
June 30, 2019 42.56%
March 31, 2019 42.28%
December 31, 2018 43.34%
September 30, 2018 42.24%
June 30, 2018 43.30%
March 31, 2018 41.39%
December 31, 2017 44.94%
September 30, 2017 44.87%
June 30, 2017 44.36%
March 31, 2017 44.94%
December 31, 2016 47.32%
September 30, 2016 44.03%
June 30, 2016 45.46%
March 31, 2016 41.95%
December 31, 2015 45.82%
September 30, 2015 41.84%
June 30, 2015 44.63%
March 31, 2015 47.26%
December 31, 2014 47.37%
September 30, 2014 47.78%
June 30, 2014 44.76%
March 31, 2014 46.77%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Ottobock SE & Co. KGaA 52.83%
Abbott Laboratories 52.64%
AngioDynamics, Inc. 50.87%
Alphatec Holdings, Inc. 62.90%
AtriCure, Inc. 76.75%